JAK2 and myeloproliferative neoplasm: Intriguingly, these individuals bearing JAK2 V617F and other CHIP somatic mutations, typically at a very low allelic burden, have increased risk of cardiovascular disease and some (but not an inevitable) risk of MPN progression.